Chemotherapy Agents Used in the COVID-19 Pandemic and Previous Years in Non-Small Cell Lung Cancer Patients and Their Effects on Periodic Mortality: A Single-Center Experience

Abstract

Objectives: The objective of the study was to evaluate chemotherapy agents used in the coronavirus disease-19 (COVID-19) pandemic and previous years and compare mortality rates of non-small cell lung cancer (NSCLC) patients whowere receiving anticancer therapy.Methods: Patients were analyzed retrospectively in three different groups; the first group (December 1, 2017-May 31,2018), the second group (December 1, 2018-May 31, 2019), and the pandemic period group (PPG) (December 1, 2019-May 31, 2020).Results: A total of 608 NSCLC patients were evaluated, 183 in the first group, 206 in the second group, and 219 in thePPG. Palliative anticancer therapy rates were 85.2% in the first group, 87.7% in the second group, and 74.4% in the PPG(p